Symptomatic effect of a long acting Lanreotide formulation in patients with gastrointestinal neuroendocrine tumours.

被引：0
|
作者：
Jacobsen, MB [1 ]
deVries, EGE [1 ]
Eriksson, B [1 ]
Fiasse, R [1 ]
Wijmenga, M [1 ]
Salmela, P [1 ]
Valimaki, M [1 ]
Oberg, K [1 ]
Renstrup, J [1 ]
机构：
[1] UNIV OSLO, OSLO, NORWAY
来源：
GASTROENTEROLOGY | 1996年 / 110卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A535 / A535
页数：1
相关论文
共 50 条
  • [21] Evaluation of Faecal Elastase 1 in Symptomatic Patients with Neuroendocrine Tumours
    Chaudhry, R.
    Newbould, R.
    Williams, M.
    Reid, K.
    Donnelly, L.
    Lewis, J.
    Khan, M.
    NEUROENDOCRINOLOGY, 2017, 105 : 144 - 144
  • [22] Lanreotide 60 mg, a new long-acting formulation: Effectiveness in the chronic treatment of acromegaly
    Attanasio, R
    Baldelli, R
    Pivonello, R
    Grottoli, S
    Bocca, L
    Gasco, V
    Giusti, M
    Tamburrano, G
    Colao, A
    Cozzi, R
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11): : 5258 - 5265
  • [23] The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel
    A. Bianchi
    L. De Marinis
    A. Fusco
    F. Lugli
    L. Tartaglione
    D. Milardi
    M. Mormando
    A. P. Lassandro
    R. Paragliola
    C. A. Rota
    S. Della Casa
    S. M. Corsello
    M. G. Brizi
    A. Pontecorvi
    Journal of Endocrinological Investigation, 2011, 34 : 692 - 697
  • [24] The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel
    Bianchi, A.
    De Marinis, L.
    Fusco, A.
    Lugli, F.
    Tartaglione, L.
    Milardi, D.
    Mormando, M.
    Lassandro, A. P.
    Paragliola, R.
    Rota, C. A.
    Della Casa, S.
    Corsello, S. M.
    Brizi, M. G.
    Pontecorvi, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2011, 34 (09) : 692 - 697
  • [25] Relationship between immunohistochemical expression and plasma concentration of total ghrelin in patients with gastric neuroendocrine tumours.
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 428 - 428
  • [26] A novel approach in the treatment of neuroendocrine gastrointestinal tumours.: Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
    Höpfner, M
    Sutter, AP
    Gerst, B
    Zeitz, M
    Scherübl, H
    BRITISH JOURNAL OF CANCER, 2003, 89 (09) : 1766 - 1775
  • [27] LanroNET - A Non-Interventional Prospective Study to Assess the Resource Utilisation and Cost of Lanreotide Autogel 120 mg in the Population of Polish Patients with Symptomatic Neuroendocrine Tumours
    Orlewska, Ewa
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    Budlewski, Tadeusz
    Jessa-Jablonska, Maria
    Houchard, Aude
    Bednarczuk, Tomasz
    ENDOKRYNOLOGIA POLSKA, 2018, 69 (05) : 567 - 572
  • [28] A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
    M Höpfner
    A P Sutter
    B Gerst
    M Zeitz
    H Scherübl
    British Journal of Cancer, 2003, 89 : 1766 - 1775
  • [29] Relationship between lanreotide autogel, chromogranin A and progression-free survival in patients with gastroenteropancreatic neuroendocrine tumours
    Buil-Bruna, N.
    Dehez, M.
    Manon, A.
    Xuan, Q. N. Thi
    Troconiz, I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S448 - S448
  • [30] Efficacy of 1-month lanreotide in patients with neuroendocrine tumours: Preliminary results of a Italian multicenter study
    Ricci, S
    Carnaghi, C
    Cirillo, F
    De Angelis, C
    Galli, C
    Iannopollo, M
    Malagutti, A
    Palmieri, G
    Stivanello, M
    Tomassetti, P
    Besozzi, A
    ANNALS OF ONCOLOGY, 2000, 11 : 61 - 61
12345